Alpha-1 Antitrypsin Deficiency in Romania : where are we and where are we need to be?

Similar documents
Rare lung diseases in Romania where are we and where we need to be?

Targeted screening programmes in COPD: how to identify individuals with α 1 -antitrypsin deficiency

Diagnosis of alpha1-antitrypsin deficiency

Corporate Medical Policy

Alpha-1 Antitrypsin Deficiency AATD

11/27/18. Challenges in Pulmonary and Critical Care: Alpha-1 Antitrypsin Deficiency: New Hope for Diagnosis and Treatment. Faculty.

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

General Guidelines for Health professionals

AATD is systemic disorder which involve GI tract: Liver Pancreas Intestine

FEP Medical Policy Manual

Spartan Medical Research Journal

Corporate Medical Policy

Lung Disease Note: You will need to provide paper towels for cleanup.

Diagnosing α 1 -antitrypsin deficiency: how to improve the current algorithm

Special Articles. Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency: Executive Summary

Policy #: 543 Latest Review Date: February 2017

How to Make AATD Screening National the Irish Experience

1 ALPHA-1. Am I an Alpha-1 Carrier? FOUNDATION FOUNDATION. Learn how being an Alpha-1 carrier can affect you and your family

9/22/2015 CONFLICT OF INTEREST OBJECTIVES. Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR

Understanding COPD - Recent Research and the Evolving Definition of COPD for MNACVPR

Lung Disease: Genes and the Environment

Florin Dumitru MIHALTAN

The IDDEA project: a strategy for the detection of alpha-1 antitrypsin deficiency in COPD patients in the primary care setting

Lab Activity Report: Mendelian Genetics - Genetic Disorders

2010 YEAR OF THE LUNG: GOALS AND OBJECTIVES. J. Randall Curtis, MD, MPH Immediate Past President, ATS

EU SUMMIT 2018 Air Pollution & mhealth Prevention and Control of Chronic Respiratory Diseases

Bronchiectasis. What is bronchiectasis? What causes bronchiectasis?

Air Pollution & mhealth Prevention and Control of Chronic Respiratory Diseases

Laboratory Testing for Alpha-1 Antitrypsin Deficiency (AATD) (Version 3.0)

What IPF Really Means: Discussions with Caregivers, Patients, & Healthcare Providers

POLICIES AND PROCEDURE MANUAL

Pharmacy Management Drug Policy

Sample blf.org.uk/copd

Respiratory diseases in Ostrołęka County

Metabolic Liver Disease

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

Basic approach to PFT interpretation. Dr. Giulio Dominelli BSc, MD, FRCPC Kelowna Respiratory and Allergy Clinic

Genetic COPD: Understanding what we know, who we test, how we treat. M. Douglas Lee, MD FCCP Wilmington Health Associates Wilmington North Carolina

INHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD)

Community Referral Program Information Packet. Imagine a world free of lung disease. Together, we can make it happen.

WF RESPIRATORY SYSTEM. RESPIRATORY MEDICINE

COPD as a comorbidity of heart failure in elderly patients

At-A-Glance report 2014

At-A-Glance report 2013

Pulmonary Rehabilitation in Chronic Lung Disease; Components and Organization. Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept.

ERS 2016 Congress Highlights Interstitial Lung Disease (ILD)

Alpha-1-antitrypsin deficiency

COPD. Helen Suen & Lexi Smith

Group B: Directed self-study Group C: Anatomy lab. Lecture: Structure and function of larynx. Lecture: Dead space & compliance of lungs

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

COPD: Genomic Biomarker Status and Challenge Scoring

Clinical. Update in Respiratory Medicine. International Symposium on. Barcelona (Spain) February 23 rd -24 th, 2018 FINAL PROGRAMME

People with asthma who smoke. The combination of asthma, a chronic airway disease, and smoking increases the risk of COPD even more.

Referring for specialist respiratory input. Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL

Alpha One Anti-Trypsin Deficiency: Challenges in Diagnosis and Treatment Final Outcome Report

Primary care diagnosis of alpha-1 antitrypsin deficiency: Issues and opportunities

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton

Infusion Management of Alpha-1 Antitrypsin Deficiency Patients. Alpha-1 Antitrypsin (AAT) the protein. AAT Deficiency (Alpha-1) 4/26/2013

MALAYSIAN THORACIC SOCIETY LUNG FUNCTION TESTS EDUCATION PROGRAMME

Division of Pulmonary, Critical Care, and Sleep Medicine, Jacksonville, FL. Department of Internal Medicine, Wichita, KS

A GUIDE TO ALPHA-1 ANTITRYPSIN DEFICIENCY

Global Patient Survey. Country-Specific Report Belgium

April 2019 Issue 32, Vol. 1. Former Smokers and Their Families Speak Out. Enter the Challenge SAVE THE DATE

ALPHA 1 -PROTEINASE INHIBITORS

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

The European Year of Volunteering 2011 What a Difference a Year Makes

Pedigree Analysis Why do Pedigrees? Goals of Pedigree Analysis Basic Symbols More Symbols Y-Linked Inheritance

Could Your Asthma or COPD be Hereditary?

COPD Awareness & Education

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

Prince Edward Island Chronic Obstructive Pulmonary Disease (COPD) Trends

PHD THESIS STUDY ON THE USE OF THE PHARMACOLOGIC THERAPY WITH BUPROPION ON TOBACCO ABSTINENCE FOR SMOKERS WITH HIGH NICOTINE DEPENDENCE

Knowledge and Practice of Medical Doctors on Chronic Obstructive Pulmonary Disease: A Preliminary Survey from a State Hospital

What do pulmonary function tests tell you?

Chronic Obstructive Lung Disease

September 16, :15 am 3:30 pm Prentice Women s Hospital 250 E. Superior St. Third Floor, Conference Room L South Chicago, Illinois 60611

Center for Respiratory and Sleep Medicine COPD Chronic Disease Management Program

UK National Screening Committee. Adult screening for COPD. 29 th June 2018

Potential risks of ICS use

Subject: Alpha1-Proteinase Inhibitors (Human)

ERS School and postgraduate education

Alpha-1 Antitrypsin Deficiency Alpha-1 Lung Disease

Lymphangioleiomyomatosis (LAM)

Breathlessness. About this information. What is breathlessness? What to do if you are concerned about getting out of breath

Fifth Annual Advances in Pulmonary and Critical Care Medicine CME Symposium

Pi ZZ Alpha 1 Antitrypsin Deficiency

Version 1.11 of 20/07/2018

Liver disease in adults with severe alpha-1-antitrypsin deficiency

In order to diagnose lung diseases doctors

Podcast Interview Transcript

Genetics Questions: There are 15 questions in total. The answers can be found on the accompanying document

MEDICAL POLICY SUBJECT: PULMONARY REHABILITATION. POLICY NUMBER: CATEGORY: Therapy/ Rehabilitation

Outcomes Summary. February 3-6, 2016 Keystone, Colorado

HARDY- WEINBERG PRACTICE PROBLEMS

European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α 1 -antitrypsin deficiency

COPD: A EUROPEAN PROBLEM WITH EUROPEAN SOLUTIONS

Online Data Supplement. Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey

Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation

ALPHA 1 -PROTEINASE INHIBITORS

Focussing on the Patient: Future Prospects in Alpha 1 Management

Transcription:

Alpha-1 Antitrypsin Deficiency in Romania : where are we and where are we need to be? Ruxandra Ulmeanu Visiting Professor, Habil, MD, PhD,FCCP Ruxandra Ulmeanu, Lavinia Davidescu, Ana Zaharie, President of the Romanian Society of Pneumology Simona Olteanu, Iulia Oita National representative GOLD,GINA,Central- Eastern European Alpha-1 Antitrypsin Network Head of Pneumology Department Faculty of Medicine Oradea Institute of Pneumology"Marius Nasta Bucharest Romania

RARE DISEASES a challenging activity for physicians

ALPHA-1 ANTITRIPSIN DEFICIENCY one of the most challenging activity for chest physicians

AATD - a disease slowly investigated Time between first symptoms and diagnosis 7.2 years ± 8.3 years Before the diagnosis is established at least 3 doctors evaluation Peter J. Barnes, Chronic Obstructive Pulmonary Disease, N Engl J Med 2000; 343:269-280

AATD in other countries represents an iceberg 5% of patients diagnosed 1. K. Stoller, A Review of a1-antitrypsin Deficiency, Am J Respir Crit Care Med Vol 185, Iss. 3, pp 246 259, Feb 1, 2012 2. Darren N. Saunders, A Novel SERPINA1 Mutation Causing Serum Alpha 1 -Antitrypsin Deficiency, PLoS One. 2012; 7(12): e51762 3. Ruxandra Ulmeanu et al, Epidemiology of AADT in Central-Eastern Europe where are we now?,first CEE -AATD Network Conference,Warsaw,19 th April 2013 4. https://en.wikipedia.org/wiki/icebergjames

before 2012 AATD in Romania frozen frozen diagnosis lake we just know that it exists Ruxandra Ulmeanu et al, Epidemiology of AADT in Central-Eastern Europe where are we now?,first CEE -AATD Network Conference,Warsaw,19 th April 2013 http://patamateria.com/tag/glass/ http://www.earthporm.com/30-amazing-photos-frozen-things/

before 2012 AATD in Romania The disease was usually identified only by the plasmatic values Genetic testing - only in the private practice with samples worked abroad and costs fully covered by the patient. Ruxandra Ulmeanu et al, Epidemiology of AADT in Central-Eastern Europe where are we now?,first CEE -AATD Network Conference,Warsaw,19 th April 2013

Genetic Screening for AATD in Romania We start to introduce the standards of the best medical practice for AATD patients in Romania since 2012

It was a complex and extremely helpful activity for Romanian team Trainings for doctors (6) biochemists (1) nurses (1) physiotherapists (1) in hospitals and laboratories from Warsaw, Hanover, Vilnius, Leiden

Still in Romania Genetic testing only in the private practice costs fully covered by the patient.

Genetic Screening for AATD in Romania goes on!!!. although Leonardo project came to an end with the support of The National Institute of Lung Diseases - Warsaw Joanna Chorostowska-Wynimko Head of Central-Eastern European Alpha-1 Antitrypsin Network

AATD in Romania? Certainly AATD in Romania is an under-diagnosed pathology in patients with COPD Ruxandra Ulmeanu,Ana Nebunoiu et al, Alpha 1 antitrypsin deficiency in Romania: preliminary results from the genetic screening 2012-2017,unpublished data

Preliminary results of Genetic Screening Romania

Protocol October 2012-present Dry blood spots Testing in Warsaw The National Institute of Lung Diseases: Plasmatic value Isoelectric focusing Genotyping Sequencing (rare cases)

Ruxandra Ulmeanu, Ana Zaharie et al, Alpha 1 antitrypsin deficiency in Romania: preliminary results from the genetic screening 2012-2017,unpublished data Gender distribution N=679 patients with available results October 2012 March 2017 More than 700 DBS have been tested (697 unique patients) 285; 40% Men 411; 60% Women AATD suspicion is higher among men Sex ratio: 1.44:1

Ruxandra Ulmeanu, Ana Zaharie et al, Alpha 1 antitrypsin deficiency in Romania: preliminary results from the genetic screening 2012-2017,unpublished data Reason for testing N=679 450 400 350 418 The main reason for testing COPD (61%), emphysema (37%) or bronchiectasis (18%) followed by asthma, siblings, other in accordance with ERS / ATS guidelines 300 250 254 200 150 126 100 50 0 87 44 35 10 COPD Emphysema Bronchiectasis Asthma Pneumothorax Siblings Other * * Other: association of: lung cancer, pulmonary fibrosis, autoimmune cirrhosis, neonatal hepatitis syndrome history, ACOS

7.5 % of screened patients were identified to have genetic modification heterozygous, more rarely homozygous Ruxandra Ulmeanu, Ana Zaharie et al, Alpha 1 antitrypsin deficiency in Romania: preliminary results from the genetic screening 2012-2017,unpublished data N=679 available results October 2012 March 2017 Normal genotype: 92.50% Modified genotype: 7.50% heterozygote c.1033g>t p.val321phe Classical mutations (80.39%) Rare mutations (19.61%)

Age distribution Minimum: The 5 average years age for testing fluctuated around 50 years, Maximum: 85 years in accordance with the decade Median: 52.00 ±16.20 when years commonly Average: AATD 50.26 is years symptomatic and diagnosed 160 140 120 100 N=679 80 60 40 20 0 October 2012 March 2017 0-10 10-20 20-30 30-40 40-50 50-60 60-70 70-80 80-90 years Ruxandra Ulmeanu, Ana Zaharie et al, Alpha 1 antitrypsin deficiency in Romania: preliminary results from the genetic screening 2012-

Ruxandra Ulmeanu, Ana Zaharie et al, Alpha 1 antitrypsin deficiency in Romania: preliminary results from the genetic screening 2012-2017,unpublished data Rare genotypes - 19.61% of mutations it may be a feature for this zone of Europe Genotype Number Percent (%) Median AAT level (mg/dl) SD (mg/dl) Average AAT level (mg/dl) M wurzburg M 4 0.15 85 36.54 88.75 IM 2 0.31 112 19.79 112 IZ 1 0.15 75 - - P lowell Z 1 0.15 undetectable plasma levels - - P lowell M 1 0.15 87 - - heterozygote c.1033g>t p.val321phe 1 0.15 179 - -

Ruxandra Ulmeanu, Ana Zaharie et al, Alpha 1 antitrypsin deficiency in Romania: preliminary results from the genetic screening 2012-2017,unpublished data Reason for testing of modified genotype N=51 1 1 1 5 11 COPD is the main indication COPD Siblings Bronchiectasis 2 Asthma 2 COPD+bronchiectasis ACOS 2 5 9 COPD+emphysema Emphysema+pneumothorax COPD+cirrhosis Others * *Others: Chronic bronchitis, interstitial fibrosis, neonatal hepatitis syndrome history

Ruxandra Ulmeanu, Ana Zaharie et al, Alpha 1 antitrypsin deficiency in Romania: preliminary results from the genetic screening 2012-2017,unpublished data COPD remains the main indication for testing at patients with modified genotype screening of first-degree relatives in 2nd bronchiectasis ranks in 3rd place refractory asthma ACOS COPD+cirrhosis until now 4.30% of patients with COPD are carriers of a modified gene

Ruxandra Ulmeanu, Ana Zaharie et al, Alpha 1 antitrypsin deficiency in Romania: preliminary results from the genetic screening 2012-2017,unpublished data The median FEV1 is 60% with large variations between 20% and 122% Fortunately, from the identified genome homozygotes 2 are children - their lung function is still in the normal range N=51 Characteristics of group with modified Parameter Median SD Minimum Maximum Age (years) 47 16.94 7 85 FEV1 (%) 60 30.34 20 122 AAT plasmatic value (mg/dl)* 99 35.13 Below the 186 sensitivity *NB: NV: 83-220 mg/dl

What else have we done for AATD in Romania?

AATD Working Group of Romanian Society of Pneumology Fouded in 2013 32 founding members June 17 th Sibiu Dr.Lavinia Davidescu Coordinator

We kept increasing the AATD awareness in Romanian medical community

We have the guideline for the diagnosis and management of AATD the version in Romanian language

Lavinia Davidescu Coordinator of AATD Working Group of the Romanian Society of Pneumology Ruxandra Ulmeanu National representative Central- Eastern European Alpha-1 Antitrypsin Network

Joanna Chorostowska-Wynimko Scientific Director National Institute of Tuberculosis & Lung Diseases, Warsaw, Poland Head of Central-Eastern European Alpha-1 Antitrypsin Network

Overview of the preliminary data for AATD screening for Romania in 2015

over 400 participants

Experts from 9 medical specialties

An exceptional involvement of young specialists, residents, students

Accession to the European AATD organizations

Romania become founding member of AATD Network of Central Eastern Europe

The presence of Romanian team

The presence of Romanian team

Relevant publications 2013-2016 The incidence of severe alpha-1-antitrypsin (AAT) deficiency alleles in COPD patients Preliminary results from Central Eastern European (CEE) AAT NETWORK Joanna Chorostowska-Wynimko, Anna Kubincova, Nikolay Yanev, Ruxandra Ulmeanu, Radoslaw Struniawski, Pavol Pobeha, Nikolay Kyuchukov, Oana Deleanu, Beata Poplawska, Ruzena Tkacova, Yavor Ivanov, Florin Dumitru Mihaltan, Arunas Valiulis, ERJ September 1, 2013 vol. 42 no. Suppl 57 P541 The incidence of severe alpha-1-antitrypsin (AAT) deficiency alleles in COPD patients Update from Central Eastern European (CEE) AAT Network Joanna Chorostowska-Wynimko, Anna Kubincova, Nikolay Yanev, Ruxandra Ulmeanu, Radoslaw Struniawski, Pavol Pobeha, Nikolay Kyuchukov, Oana Deleanu, Beata Poplawska-Wisniewska, Ruzena Tkacova, Yavor Ivanov, Florin Mihaltan, Arunas Valiulis, ERJ September 2014 vol. 44 no. Suppl 58 2035;

Relevant publications 2013-2016 Alpha-1 Antitrypsin Deficiency in Romania First Steps (Results of First Three Years of Screening) R. Ulmeanu, A.-M. Zaharie, J. Chorostowska Wynimko, O.C. Deleanu, F.D. Mihaltan, American Journal of Respiratory and Critical Care Medicine 2016;193:A1574 Alpha-1 antitrypsin deficiency do we really understand it? Case presentations. Ana-Maria Zaharie, Florin Dumitru Mihaltan, Cristian Popa, Oana Claudia Deleanu, Ruxandra Ulmeanu, American Journal of Respiratory and Critical Care Medicine 2016;193:A1576

Relevant publications Journal of Romanian Society of Pneumology 2013-2016

and starting with 2015 Romania was repesented at The Biennial Alpha-1 Global Patient Congress and International Research Conference 2015,2016,2017 Simona Olteanu Romanian patients representative Lavinia Davidescu Coordinator of Romanian AATD Working Group The Romanian stand Hillegonda Guttierez Alpha 1 Global Director

Alpha -1 Global website Romanian page Bine ati venit la Pagina Romaniei Deficitul de Alfa 1 Antitripsina

First flyer with information about AATD for romanian patients I have to mention the special activity of Mrs. Simona Olteanu

Simona Olteanu a lovely lady a powerful and unique mother a wonderful partner in patient-physician team The author of informative materials for patients http://www.alfa1.ro/

The official Romanian website for Alpha-1 Antitrypsin Deficiency www.alfa1.ro Was founded in 2016 with the support of the Romanian Society of Pneumology

The National Register of Alpha-1 Antitrypsin Deficiency www.alfa1.ro/registru Dr. Ana Zaharie an exceptional young pneumologist Coordinator of AATD screening Was founded in 2016 with the support of the Romanian Society of Pneumology

The National Register of Alpha-1 Antitrypsin Deficiency a unique code, date of birth, sex, age, county

The National Register of Alpha-1 Antitrypsin Deficiency the menu for the first data - the reason for testing, other members tested, spirometry, phenotype and plasma value

The National Register of Alpha-1 Antitrypsin Deficiency 1st evaluation, last evaluation, current evaluation

The National Register of Alpha-1 Antitrypsin Deficiency spirometry and plethysmography - successive assessments

The National Register of Alpha-1 Antitrypsin Deficiency other important clinical data arterial blood gases, 6 minutes walking test

Novelties Interactive Session with Patients Associations

Novelties Interactive Session with Patients Associations Frank Willersinn Alpha-1 Global & Alpha-1 Foundation Bruxelles, Belgium

Interactive session title was Saturday October 8th, 2016

Alpha 1 Global - guest of honor of Romanian Society of Pneumology Indeed Alpha 1 Global is a model to follow we hope that this model will be essential for alpha patients from Romania

We must say that there is a significant problem in Romania Still does not exist associations for patients with lung diseases due to excessive bureaucracy fear of the authorities the feeling of hopelessness patients with chronic lung diseases older than 50 years lived under communism when these mentalities were dominant

Romanian Society of Pneumology attended for the 1 st time the International Conference of Patients with Rare Diseases organized by Romanian Patients Alliance For Rare Diseases 8 th February 2017

Romanian Society of Pneumology attended the International Conference of Patients with Rare Diseases It is hopeful that this year our Society discussed for the first time the huge problem represented by rare lung diseases in Romania, especially AATD and IPF

Patients Alliance For Rare Diseases Romania accepted the invitation to be partner of The 2nd National Conference of Rare Lung Diseases 12-14 October 2017 Oradea Romania

Summarizing

More than 700 patients screened Mostly heterozygotes Rare genotypes Mostly in COPD patients

establishing a national reference laboratory Screening for AATD creating a national database for patients in Romania goes on! identified with AATD

We'll do more two powerful ladies two wonderful partners in patient-physician team Simona Olteanu Iulia Oita

Thank you for your invitation and for the opportunity to talk about the problems of alpha patients from Romania

At the same time we will be happy and honored if Alpha-1 global will accept our invitation to be partner of The 2nd National Conference of Rare Lung Diseases 12-14 October 2017 Oradea, Romania http://srp.ro/

The Network of AATD in Central and Eastern Europe

http://srp.ro/ http://www.alfa1.ro/